Your session is about to expire
← Back to Search
BHV-7000 75 mg for Epilepsy (RISE 3 Trial)
RISE 3 Trial Summary
This trial aims to find out if BHV-7000 is helpful in treating focal epilepsy that has not responded well to other treatments.
RISE 3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RISE 3 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this study allow individuals who are at least 18 years old to participate?
"Potential participants must be between the ages of 18 and 75 to meet the study's eligibility criteria. Specifically, there are 105 trials for individuals under 18 years old and 167 studies targeting those over 65."
Are multiple medical facilities in Canada conducting this research study?
"The current trial is operational at 12 sites, with bases in Miami, Charleston, and Chattanooga among others. Opting for the nearest location can reduce travel requirements for potential participants."
Do I meet the necessary requirements to participate in this clinical investigation?
"Individuals diagnosed with epilepsy within the age range of 18 to 75 are eligible for participation in this research study, which has a total capacity of 390 participants."
Are new participants currently being recruited for this ongoing medical study?
"The information on clinicaltrials.gov shows that patient recruitment for this study is closed. The trial was first listed on March 1, 2024, and the most recent update was made on March 8, 2024. Despite this trial no longer accepting participants, there are currently 251 other trials actively seeking patients to enroll in their studies."
Share this study with friends
Copy Link
Messenger